Introduction: It is unknown how frailty evolves over time in patients with hepatocellular carcinoma who are treated with locoregional therapies (LRTs). Methods: We conducted a retrospective study of LRT-treated hepatocellular carcinoma patients with Liver Frailty Index (LFI) assessments. Linear mixed-effects modeling was used to assess the impact of time (modeled linearly per month) and other variables on LFI. *Results: Of 201 patients enrolled, median baseline LFI was 3.54. LFI did not change significantly over time from study entry (P = 0.93). Discussion: In our study, LFI remained stable over time after LRT, suggesting that LRT is generally well tolerated.